IP Verse

Methods Of Treating Uterine Fibroids And Endometriosis - EP3518933

The patent EP3518933 was granted to Myovant Sciences on Feb 26, 2025. The application was originally filed on Sep 29, 2017 under application number EP17823018A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3518933

MYOVANT SCIENCES
Application Number
EP17823018A
Filing Date
Sep 29, 2017
Status
Patent Maintained As Amended
Jan 24, 2025
Grant Date
Feb 26, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZDec 15, 2022KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS7300935
DESCRIPTIONUS8058280
DESCRIPTIONUS8735401
DESCRIPTIONUS9346822
DESCRIPTIONUS9758528
DESCRIPTIONWO2016136849
INTERNATIONAL-SEARCH-REPORTWO2014143669
OPPOSITIONEP0074907
OPPOSITIONUS402034
OPPOSITIONUS402055
OPPOSITIONUS402150
OPPOSITIONUS492839
OPPOSITIONUS528409
OPPOSITIONWO2014143669

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- HORNSTEIN M D ET AL, "Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199801), Database accession no. NLM9464714, XP002779261-
EXAMINATION- HORNSTEIN M D ET AL, "Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.", OBSTETRICS AND GYNECOLOGY JAN 1998, (199801), vol. 91, no. 1, doi:10.1016/S0029-7844(97)00600-5, ISSN 0029-7844, pages 16 - 24, XP029904758
OPPOSITION- A. Al-Hendy et al., N. Engl. J. Med., 2021, 284(7), 630-642-
OPPOSITION- Anonymous, "Form 10-Q United States Securities And Exchange Commission", Myovant Sciences Ltd., (20160101), Myovant Sciences Ltd., (20230110), XP093012525-
OPPOSITION- Anonymous, "Form S-1 Registration Statement under the Securities Act", Myovant Sciences Ltd, (19930101), Myovant Sciences Ltd, (20230110), XP093012502-
OPPOSITION- Anonymous, "Form S-1", Wikipedia, (20220620), Wikipedia, (20230110), XP093012508-
OPPOSITION- Anonymous, "HISTORY OF CHANGES FOR STUDY NCT02655224", ClinicalTrials.gov, (20160101), ClinicalTrials.gov, (20230110), XP093012530-
OPPOSITION- Anonymous, "HISTORY OF CHANGES FOR STUDY NCT02655237", ClinicalTrials.gov, (20160101), ClinicalTrials.gov, (20230110), XP093012529-
OPPOSITION- Anonymous, "HISTORY OF CHANGES FOR STUDY NCT03204318", ClinicalTrials.gov, (20170101), ClinicalTrials.gov, (20230110), XP093012535-
OPPOSITION- Anonymous, "HISTORY OF CHANGES FOR STUDY NCT03204331", ClinicalTrials.gov, (20170101), ClinicalTrials.gov, (20230110), XP093012539-
OPPOSITION- Anonymous, "Human Reproduction vol. 32", Geneva, Switzerland, (20170101), XP093012495-
OPPOSITION- Anonymous, "Myovant sciences Announces Late-Breaking oral Presentation of phase 3 Liberty 1&2 Study Results", Myovant Sciences, (20191010), Myovant Sciences, (20230110), XP093012501-
OPPOSITION- Anonymous, "Myovant Sciences announces Presentation of Positive Phase 2 Data for Relugolix in Women with heavy menstrual bleeding and Uterine Fibroids at the annual meeting of the American Congress of Obstetricians and Gynecologists", Myovant Sciences, (20170507), Myovant Sciences, (20230110), XP093012545-
OPPOSITION- Anonymous, "Roivant Sciences and Takeda Launch Myovant Sciences", Takeda press release, (20160607), Takeda press release, (20230110), XP093012511-
OPPOSITION- Attar, R. et al., Women’s Health 2015, 11(5), 653-664;-
OPPOSITION- C. Becker et al., Session 62, Abstracts of the 38th Hybrid Annual Meeting of the ESHRE, 3 6 July 2022, page i1 10-
OPPOSITION- Chwalisz, K. et al., “Fibroids”, First Edition, edited by James H. Segars, John Wiley & Sons, Ltd., 2013, Chapter 6 entitled “Medical Management of Women with Symptomatic Uterine Fibroids”-
OPPOSITION- ClinicalTrials.gov archive, History of Changes for Study NCT02655224, last update submitted September 13, 2016 and posted on 15 September 2016-
OPPOSITION- ClinicalTrials.gov archive, History of Changes for Study NCT02655237, last update submitted September 13, 2016 and posted on 15 September 2016-
OPPOSITION- Frances Batzer R., "GnRH agonist and antagonist: options for endometriosis pain treatment", Thomas Jefferson University, (20061101), Thomas Jefferson University, (20230110), XP093012513-
OPPOSITION- I. Duijkers et al., P-287, Abstracts of the 36th Annual Meeting of the ESHRE, 5 to 8 July 2020, page i268-i269-
OPPOSITION- L. C. Giudice et al., placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-2022; 399: 2267 79, published 25 August 2022-
OPPOSITION- McLaren, J.S. et al., Menopause Int. 2012, 18, 68-72;-
OPPOSITION- Myovant Sciences + Pfizer publication in The Lancet of Phase 3 Spirit 1 and Spirit 2 studies of oncedaily relugolix combination therapy in women with endometriosis-, published 17 June 2022-
OPPOSITION- S. As-Sanie et al., O-1, ASRM 2022 Genes, Gametes, and Genetics, October 22-26 2022, Scientific Abstracts to be presented at the 78th Scientific Congress of the American Society for Reproductive Medicine, October 22-26, 2022, Anaheim, California, page e1-
OPPOSITION- Wu, D. et. al., Arch. Gynecol. Obstet. 2014, 513-523;-
OPPOSITION- Midgley Gonzales; Leandro Accardo de Matos; Manoel Orlando da Costa Gonçalves; Roberto Blasbalg; João Antà ́nio Dias Junior; Sérgio Podgaec; Edmund Chada Baracat; Maurício Simões Abrão, "Patients with adenomyosis are more likely to have deep endometriosis", Gynecological Surgery ; Endoscopy, Imaging, and Allied Techniques, Springer, Berlin, DE, Berlin, DE , (20120503), vol. 9, no. 3, doi:10.1007/s10397-012-0746-4, ISSN 1613-2084, pages 259 - 264, XP035088403
OPPOSITION- Dong-Yun Lee, Hyang Gi Park, Byung-Koo Yoon, Dooseok Choi, "Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis", Obstetrics & Gynecology Science, (20160101), vol. 59, no. 1, doi:10.5468/ogs.2016.59.1.32, ISSN 2287-8572, page 32, XP055304542

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents